ASH 2024 preview – more challenges to the BTK order
First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.
Triple meeting 2024 – Tyra’s targeted FGFR3 push
The company reckons it’s got what it takes to hit the right member of the FGFR family.
Not so B-Fast for Roche
The focus for divarasib in second-line lung is now the head-to-head Krascendo-1 trial.
Triple meeting 2024 – plenary focus
Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.
KRAS strikes back
First-in-human trial initiations reveal four KRAS assets.
